PharmaShots | Incisive News in 3 Shots

Subscribe Now

Breakthrough Therapy

Boehringer Ingelheim's Ofev (nintedanib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

Boehringer Ingelheim's Ofev (nintedanib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a...

October 11, 2019

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukaemia (CLL) in Adults

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukae...

August 14, 2019

AstraZeneca's Selumetinib Receives the US FDA's Breakthrough Therapy Designation for Neurofibromatosis Type 1

AstraZeneca's Selumetinib Receives the US FDA's Breakthrough Therapy Designation for Neurofibromatosis Type 1

April 1, 2019

Novartis's SEG101(crizanlizumab) Receives FDA's Breakthrough Therapy(BT) Designation for Sickle Cell Disease

Novartis's SEG101(crizanlizumab) Receives FDA's Breakthrough Therapy(BT) Designation for Sickle Cell Disease

January 8, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us